antimalarial agent-1

Antimalarial agent 1 is an effective antimalarial agent.

Antimalarial agent 30 has anti-Plasmodium berghei liver stage parasite activity and antimalarial activity for the study of malarial infections.

Antiulcer Agent 1 is an orally administered derivative of 2-(3,4-dimethoxyphenyl)ethylamine.

Antimalarial agent 13 (N2-(3-chlorophenyl)-N4-(furan-2-ylmethyl)quinazoline-2,4-diamine) is a potent antimalarial agent.

Acetic acid, 2-[4-[(2-ethyl-3-benzofuranyl)carbonyl]phenoxy]- is a compound used for antiviral activity determinations.

Anxiolytic/nonsedative agent-1 (TCS 1205) is a potent and selective GABAA agonist. Anxiolytic/nonsedative agent-1 shows appreciable affinity for the BzR in bovine brain membranes with Kis of 14, 121, 239 nM for α1β2γ2, α2β2γ2, α5β3γ2, respectively. Anxiolytic/nonsedative agent-1 shows α2 selective efficacy in vitro and anxioselective effects in vivo.

Anti-TB agent 1 is a potent and orally active anti-tuberculosis compound (MICs: < 2 nM against the Mtb strains H37Rv, rRMP, and rINH).

ethyl 2-[3,5-bis(trifluoromethyl)phenyl]-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate is a synthetic compound belonging to the curcumin family. It is involved in the regulation of immune response and inflammation through inhibition of the NF-κB signaling pathway, in the regulation of antioxidant response through activation of the Nrf2 signaling pathway, and in the regulation of cell survival and proliferation through inhibition of the Akt signaling pathway.

Anticonvulsant agent 1 is a chemical compound with potent anticonvulsant properties.

Antimalarial agent 14 (NSC-102533) is a bioactive chemical.

GABAA receptor agent 1 has strong anticonvulsant activity and is a high affinity ligand of GABAA receptor.

Antitrypanosomal agent 1 is a potent and selective trypanothione reductase (TR) inhibitor (IC50: 3.3 μM) that also inhibits glutathione reductase (IC50: 64.8 μM) and T. brucei (EC50: 1 μM).

Compound 29 (also known as Compound 16) is an antimalarial agent that demonstrates inhibition of the P. berghei liver stage parasite load, exhibiting an effective concentration (EC50) of 5.2 μM [1].

Compound 24 (Compound 7), an in vitro antimalarial agent, demonstrates inhibitory activity against the Plasmodium falciparum W2 strain with an IC50 of 0.81 μM and exhibits a cytotoxicity threshold (CC50) exceeding 200 μM in HepG2 cells [1].

Antimalarial agent 28 (Compound 2i) is an antiplasmodial agent that inhibits P. berghei with IC50 values of 0.561 μM for the liver stage, 0.14 μM for early gametocytes, and 4.34 μM for the ring stages of P. falciparum [1].

Antimalarial agent 33 (compound 5g) exhibits antiplasmodial activity targeting both erythrocytic and hepatic stages of Plasmodium, with an effective concentration (EC50) of 1.1 μM against the K1 strain of P. falciparum. It demonstrates improved microsomal stability with a half-life (T1 2) of 29 minutes and displays no significant cytotoxicity against primary hepatocytes [1].

Compound 31 (compound 7k) is an orally active inhibitor of Plasmodium falciparum aspartic protease, plasmepsin X (PMX), with antimalarial properties [1].

Antimalarial agent 26, a derivative of 1,4-naphthoquinones, demonstrates antimalarial properties through oral administration. It exhibits cytotoxic effects on P. falciparum while maintaining selectivity against mammalian cell lines and effectively inhibits P. berghei-induced parasitemia in vivo [1].

Antimalarial agent 25, a derivative of 1,4-naphthoquinones, demonstrates oral activity and is effective against malaria. It exhibits cytotoxic properties specifically targeting P. falciparum and effectively inhibits parasitemia induced by P. burghei in vivo [1].

Antimalarial agent 23, a benzimidazole-based compound, exhibits potent antimalarial activity, demonstrated by its low IC50 values of 0.08 μM for PfNF54 and 0.10 μM for PfK1, respectively. This compound effectively inhibits β-hematin formation, yet it does not directly interfere with the conversion of heme to hemozoin [1].

Antimalarial agent 17, functioning both as an antimalarial agent and a herbicide, inhibits photosystem II and demonstrates post-emergence herbicidal efficacy comparable to commercial herbicides [1].

Antimalarial agent 11 (compound 1), a spirocyclic chromane, is a potent antimalarial agent effective against D6 (EC50: 1.48 μM) and ARC08-022 (EC50: 1.81 μM).

Antimalarial agent 27 (compound 11a) potently inhibits P. falciparum with an IC50 of 0.37 μM, targeting the parasite's 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme with an IC50 of 0.11 μM, indicating its mechanism of action [1].

Antimalarial agent 36 (compound 1), exhibiting EC50 values of 58 nM and 42 nM against Dd2 and 3D7 strains respectively, is an efficacious antimalarial agent. It specifically targets EphA2 [1].

Antimalarial agent 37 (compound 33), a selective Type Ⅱ kinase inhibitor, exhibits antiplasmodial activity and demonstrates cytotoxicity towards HepG2 and MCF 7 cancer cells [1].

Antimalarial agent 19 (compound 6e) exhibits antimalarial activity against the blood stages of P. falciparum K1 and P. berghei, with EC50 values of 0.3 µM and 15.3 µM, respectively. It demonstrates good aqueous solubility, intestinal permeability, and microsomal stability relative to gamhepathiopine [1].

Anti-aging agent 1 (compound 24), a piperlongumine (PL) derivative, demonstrates a significant enhancement in senolytic activity, being 50 times more effective against senescent WI-38 fibroblasts than PL [1].

Hepatoprotective agent-1 (compound 1b) functions as a hepatoprotective agent, exhibiting anti-inflammatory, antiapoptotic, and antifibrotic effects [1].

Compound 3l, a paclitaxel derivative known as Microtubule Stabilizing Agent-1, effectively enhances tubulin polymerization and demonstrates antitumor efficacy [1].

Anti-amyloid agent-1 is a potent compound that inhibits amyloid aggregation, offering a promising approach for research into the treatment of amyloidosis [1].

Antimalarial agent 15 is a parasite inhibitor that exhibits antimalarial effects and inhibits the growth of Plasmodium falciparum 3D7 with an IC50 value of 20 nM.

Anti-Trypanosoma cruzi agent-1 (Compd E5) demonstrates a potent anti-Toxoplasma effect.

Anti-neurodegeneration agent 1, a neurodegeneration-targeting agent.

Antileishmanial agent-1 demonstrates activity against both L. amazonensis promastigotes (IC 50 = 15.52 μM) and intracellular amastigotes (IC 50 = 4.10 μM).

Anti-MRSA agent 1 is an MRSA inhibitor with an MIC value of 0.5 μg/mL and is effective in alleviating the effects of MRSA resistance.

Anti-melanoma agent 1 (Compound 5m) is an apoptotic inducer in melanoma cells.

Analgesic agent-1 is a potent analgesic that exhibits significant analgesic activity.

Anti-TSWV agent 1 is a highly effective inactivator (EC50:144 μg/mL) of tomato spotted wilt virus (TSWV).

Antimalarial agent 9 is an effective antimalarial agent, a quinoline-imidazole derivative compound. antimalarial agent 9 showed significant in vitro antimalarial effects against CQ-susceptible strains (IC50-0.14 μM) and MDR strains (IC50-0.41 μM), with minimal cytotoxicity and high selectivity.

Anti-osteoporosis agent-1 (comp 4aa) is a potent RPA (replication protein A) inhibitor with an IC50 value of 18 μM [1].

Lipid-lowering agent-1 is a potent lipid-lowering compound that significantly inhibits the pharmacological effects of low-density lipoprotein cholesterol (LDLC) and promotes high-density lipoprotein cholesterol (HDLC) production. In rats on a high-fat diet, it substantially reduces fat.

Therapeutic Agent-1, a heteroaryl compound, serves as an enzyme replacement therapy to enhance glucocerebrosidase activity in the treatment of Gaucher disease [1].

Anti-NASH Agent 1 (Compound 3d), derived from Elafibranor, serves as a strong PPAR-α/δ agonist aimed at treating nonalcoholic steatohepatitis (NASH). At dosages of 3-10 mg/kg over four weeks, this compound ameliorates hyperlipidemia, liver fat degeneration, and inflammation in a methionine-choline deficiency (MCD)-induced NASH mouse model, exhibiting minimal hepatotoxicity while providing substantial hepatic protection [1].

Herbicidal agent 1 ((S)-6q) exhibits superior activity compared to its racemic form [1].

Antimalarial agent 8 (Compound 7e) is a novel, orally active antimalarial effective against P. falciparum in vitro and in vivo in a mouse model of malaria at 40 mg kg.

Anti-Heart Failure Agent 1 is an orally available compound suitable for treating heart failure without causing vomiting, nausea, or restlessness.

Anti-hyperglycemic agent 1 is a potent inhibitor of alpha-glucosidase (IC50: 0.53 μM). anti-Hyperglycemic agent 1 can be used to study diabetes.

Bronchospasmolytic agent 1 is a flutropium bromide compound and acts as a bronchospasmolytic agent.